Entellus Medical (NASDAQ: ENTL) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitabiliy and valuation.
Profitability
This table compares Entellus Medical and Penumbra’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entellus Medical | -39.02% | -60.56% | -35.90% |
| Penumbra | -2.31% | -2.25% | -1.96% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Entellus Medical and Penumbra, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entellus Medical | 1 | 2 | 4 | 0 | 2.43 |
| Penumbra | 0 | 0 | 2 | 0 | 3.00 |
Entellus Medical presently has a consensus target price of $22.00, indicating a potential upside of 30.87%. Penumbra has a consensus target price of $95.00, indicating a potential upside of 18.60%. Given Entellus Medical’s higher possible upside, equities analysts plainly believe Entellus Medical is more favorable than Penumbra.
Risk and Volatility
Entellus Medical has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
Institutional and Insider Ownership
76.1% of Entellus Medical shares are owned by institutional investors. Comparatively, 69.0% of Penumbra shares are owned by institutional investors. 9.1% of Entellus Medical shares are owned by company insiders. Comparatively, 22.0% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Entellus Medical and Penumbra’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Entellus Medical | $77.39 million | 4.76 | -$25.43 million | ($1.56) | -10.78 |
| Penumbra | $278.61 million | 9.67 | -$2.82 million | ($0.21) | -381.43 |
Penumbra has higher revenue and earnings than Entellus Medical. Penumbra is trading at a lower price-to-earnings ratio than Entellus Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Penumbra beats Entellus Medical on 10 of the 13 factors compared between the two stocks.
Entellus Medical Company Profile
Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company’s XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.
Penumbra Company Profile
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
